MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-10-2025
uniQure N.V. Market Cap 2011-2026 | QURE
As of January 20, 2026 uniQure N.V. has a market cap of $ 1.09 B
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap uniQure N.V.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 587 M | 322 M | 978 M | 830 M | 1.57 B | 2.37 B | 1.18 B | 526 M | 138 M | 403 M | 360 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.37 B | 138 M | 843 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
315 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aeterna Zentaris
AEZS
|
41.4 M | - | 5.93 % | $ 314 M |  Canada |
 |
Adagene
ADAG
|
87.8 M | $ 1.9 | -3.11 % | $ 107 M |  China |
 |
Acorda Therapeutics
ACOR
|
16.7 M | - | -24.86 % | $ 820 K |  USA |
 |
AgeX Therapeutics
AGE
|
14.1 K | - | -10.17 % | $ 12.2 K | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
1.31 B | $ 25.88 | -0.73 % | $ 1.25 B | USA |
 |
Alterity Therapeutics Limited
ATHE
|
895 M | $ 3.31 | -4.06 % | $ 7.96 B |  Australia |
 |
Aptose Biosciences
APTO
|
2.32 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aravive
ARAV
|
60.4 M | - | -13.39 % | $ 1.45 M | USA |
 |
Aytu BioScience
AYTU
|
15.8 M | $ 2.7 | 1.5 % | $ 17 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
33.6 B | - | - | $ 40.3 B | USA |
 |
AVROBIO
AVRO
|
56.3 M | - | 1083.1 % | $ 745 M | USA |
 |
Biophytis SA
BPTS
|
549 M | - | -13.47 % | $ 169 M |  France |
 |
Aeglea BioTherapeutics
AGLE
|
724 M | - | - | $ 1.01 B | USA |
 |
Midatech Pharma plc
MTP
|
79 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
28.9 M | - | -1.52 % | $ 24.7 M | USA |
 |
Akero Therapeutics
AKRO
|
3.25 B | - | - | $ 3.67 B | USA |
 |
Brickell Biotech
BBI
|
11.4 M | - | -5.38 % | $ 6.06 M | USA |
 |
BioLineRx Ltd.
BLRX
|
1.35 B | $ 2.9 | 0.52 % | $ 908 M |  Israel |
 |
BeiGene, Ltd.
BGNE
|
253 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
BioNTech SE
BNTX
|
62.9 B | $ 106.07 | -2.69 % | $ 27.2 B | Germany |
 |
Akouos
AKUS
|
172 M | - | 0.23 % | $ 488 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
3.16 B | $ 3.96 | -1.0 % | $ 8.62 B | Israel |
 |
CASI Pharmaceuticals
CASI
|
1.09 B | $ 0.95 | -0.72 % | $ 129 M | USA |
 |
Applied Molecular Transport
AMTI
|
22.1 M | - | - | $ 10.1 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
2.83 B | - | - | - |  Russia |
 |
Ascendis Pharma A/S
ASND
|
7.37 B | $ 215.17 | 4.54 % | $ 5 B |  Danmark |
 |
Bellicum Pharmaceuticals
BLCM
|
8.32 M | - | -9.72 % | $ 5.89 M | USA |
 |
ARCA biopharma
ABIO
|
484 M | - | 1052.0 % | $ 415 M | USA |
 |
Bio-Path Holdings
BPTH
|
2.94 M | - | - | $ 100 K | USA |
 |
Acasti Pharma
ACST
|
40.7 M | - | 4.01 % | $ 150 M | Canada |
 |
Baudax Bio
BXRX
|
779 K | - | 0.59 % | $ 63 K | USA |
 |
Celldex Therapeutics
CLDX
|
1.31 M | $ 25.17 | -1.89 % | $ 1.62 M | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
6.25 B | $ 64.51 | 1.04 % | $ 8.63 B | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
2.44 B | $ 23.24 | 2.38 % | $ 2.75 B | USA |
 |
Burford Capital Limited
BUR
|
2.09 B | $ 9.65 | -0.72 % | $ 1.56 B | Britain |
 |
Ayala Pharmaceuticals
AYLA
|
7.72 M | - | - | $ 7.46 M | Israel |
 |
Adaptimmune Therapeutics plc
ADAP
|
2.05 B | - | -15.15 % | $ 60.3 M | Britain |
 |
AIkido Pharma
AIKI
|
19.6 M | - | 1.93 % | $ 17.4 M | USA |
 |
Albireo Pharma
ALBO
|
538 M | - | -0.23 % | $ 916 M | USA |
 |
CureVac N.V.
CVAC
|
3.53 B | - | - | $ 867 M | Germany |
 |
Acer Therapeutics
ACER
|
12.1 M | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
269 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
49 M | - | 4.14 % | $ 49.1 M | USA |
 |
Catalyst Biosciences
CBIO
|
33.6 M | $ 14.0 | 3.63 % | $ 922 M | USA |
 |
Biogen
BIIB
|
19.3 B | $ 164.49 | 0.04 % | $ 23.9 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
664 K | - | -11.43 % | $ 502 K | USA |
 |
Avid Bioservices
CDMO
|
423 M | - | - | $ 789 M | USA |
 |
BioVie
BIVI
|
2.44 M | $ 1.24 | 2.49 % | $ 1.83 M | USA |
 |
Calithera Biosciences
CALA
|
960 M | - | -10.95 % | $ 876 K | USA |